Citicoline vs alpha-GPC

People often compare citicoline with alpha-GPC because both supply choline, a nutrient the body uses to build cell membranes and the signaling molecule acetylcholine. That is a fair starting point, but the evidence behind the two compounds is not the same, and there is no head-to-head winner to declare. No trial has directly compared them in people, so this article compares what is known about each on its own terms.

The first thing to get right is naming. Citicoline (CDP-choline) is one compound with two names, and Cognizin is a brand of it. Alpha-GPC is a different compound with its own chemistry. In the United States, both are sold as dietary supplements, not as FDA-approved drugs. That means label claims should be read with care on both sides.

On the citicoline side, the strongest human result is actually a negative one, and readers deserve to hear it plainly. The large ICTUS trial (Dávalos, Lancet 2012, about 2,300 people) found citicoline did not improve 90-day recovery after acute stroke compared with placebo. Earlier meta-analyses had suggested a benefit, but ICTUS did not confirm it. COBRIT (Zafonte, JAMA 2012) similarly found no benefit in traumatic brain injury. Softer positives exist for chronic cerebrovascular cognitive decline and adult attention, but with limits we explain below. For alpha-GPC, this comparison does not cite an equivalent approved evidence set, and we will not borrow citicoline's stroke trial, in either direction, to fill that gap.

Evidence at a glance

Why there is no head-to-head winner

A fair comparison needs a trial that randomizes people to citicoline or alpha-GPC and measures the same outcomes. No such trial appears in the register we work from. Without it, claims that one is "stronger" or "better absorbed in a way that matters clinically" go beyond the data. Both deliver choline by different chemical routes, but delivery is not the same as a proven health outcome.

What the citicoline evidence actually shows

The biggest and best-conducted citicoline trials are negative. ICTUS, with about 2,300 stroke patients, found no improvement in 90-day recovery versus placebo, and it did not confirm the benefits earlier meta-analyses had suggested. COBRIT found the same pattern in traumatic brain injury: no improvement in functional or cognitive outcomes.

Where citicoline looks more favorable, the evidence is weaker. The Cochrane review by Fioravanti and Yanagi found modest short-term benefit on memory and behaviour in chronic cerebrovascular cognitive decline, but the trials were short and low quality. IDEALE was observational, not randomized: people taking citicoline had stable scores while an untreated group declined, which is suggestive but not proof. The McGlade attention studies in adult women and adolescent males showed better test scores at 250/500 mg, but they were small and funded by the maker of Cognizin. There is no adequate evidence that citicoline treats ADHD.

How the two compounds differ on paper

Citicoline breaks down into choline and cytidine, and at a mechanistic level it may support membrane phospholipid synthesis. That neuroprotection idea, though, is preclinical only, it has not been shown to translate into better outcomes in the large human trials. Alpha-GPC also supplies choline, but this article does not carry an approved evidence set for it, so we do not grade its claims here. The honest summary is that "different molecule" does not mean "proven better molecule."

Safety and practical points

Citicoline was generally well tolerated in trials at 250, 2,000 mg per day. Reported side effects were mild: stomach upset, headache, and insomnia. Data in pregnancy and breastfeeding are lacking. Citicoline may enhance the effects of levodopa, so people with Parkinson's disease should involve their neurologist before using it. In the US, both citicoline and alpha-GPC are dietary supplements, not FDA-approved drugs, so quality and dosing are not regulated the way medicines are.

Expert insight

When patients ask me "citicoline or alpha-GPC," my first answer is that no trial has compared them directly, so nobody can honestly crown a winner. My second answer is that citicoline's largest trials are negative: ICTUS showed no benefit for stroke recovery, and COBRIT showed none for brain injury. The positive signals I can point to, a Cochrane review in chronic cerebrovascular cognitive decline, and small industry-funded attention studies, sit at lower tiers of evidence. Alpha-GPC is a genuinely different compound, and difference alone is not evidence of superiority. I would also remind anyone on levodopa to speak with their neurologist before adding citicoline. Read the register for what it is, not for what marketing wants it to be.

Questions readers ask

Is citicoline the same thing as CDP-choline?

Yes. Citicoline and CDP-choline are two names for one compound. Cognizin is a branded form of it.

Is alpha-GPC the same as citicoline?

No. They are different compounds that both supply choline. They should not be treated as interchangeable on a label or in a study.

Which one is proven better?

Neither. No head-to-head trial exists. On the citicoline side, the largest trials (stroke and brain injury) were negative, and the positive findings are small, short, or industry funded.

Did citicoline help people after stroke?

No, not in the best test. The ICTUS trial of about 2,300 people found no improvement in 90-day recovery versus placebo. Earlier meta-analyses suggested benefit, but ICTUS did not confirm that.

Does citicoline help with attention or ADHD?

Small, industry-funded trials in adult women and adolescent males showed better attention-test scores. There are no adequate trials for ADHD, so there is no good evidence it treats ADHD.

Is citicoline safe?

In trials at 250, 2,000 mg per day it was generally well tolerated, with mild stomach upset, headache, or insomnia in some people. Pregnancy and breastfeeding data are lacking.

Can I take citicoline with Parkinson's medication?

Citicoline may enhance levodopa's effects. People with Parkinson's should involve their neurologist before using it.

Are these supplements FDA approved?

No. In the United States both are sold as dietary supplements, which are not FDA-approved drugs.

Sources

Sources named in this article: ICTUS (Dávalos, Lancet 2012); earlier stroke meta-analyses; COBRIT (Zafonte, JAMA 2012); Cochrane review on chronic cerebrovascular cognitive decline (Fioravanti and Yanagi); IDEALE (Cotroneo); McGlade 2012 adult attention study; McGlade adolescent attention study; small glaucoma trials (Parisi; Rossetti groups). PMIDs are not listed until each one is confirmed on PubMed.

For more, see our comparison hub, the dedicated citicoline vs alpha-GPC comparison page, the citicoline overview, the full evidence register, and our guides to side effects and dosage.